Literature DB >> 21897785

Sodium oxybate post-marketing surveillance.

Neil T Feldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21897785      PMCID： PMC3161780          DOI： 10.5664/JCSM.1216

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


× No keyword cloud information.
  4 in total

Review 1.  Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion.

Authors:  Y Grace Wang; Todd J Swick; Lawrence P Carter; Michael J Thorpy; Neal L Benowitz
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

2.  Influence of physicians' attitudes on reporting adverse drug events: a case-control study.

Authors:  A Figueiras; F Tato; J Fontaiñas; J J Gestal-Otero
Journal:  Med Care       Date:  1999-08       Impact factor: 2.983

3.  Under-reporting of serious adverse drug reactions in Sweden.

Authors:  M Bäckström; T Mjörndal; R Dahlqvist
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-07       Impact factor: 2.890

Review 4.  Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing.

Authors:  Neil T Feldman
Journal:  Sleep Breath       Date:  2009-07-23       Impact factor: 2.816
  4 in total
  1 in total

Review 1.  A practical guide to the therapy of narcolepsy and hypersomnia syndromes.

Authors:  Emmanuel J M Mignot
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.